Prostate cancer
Conditions
Interventions
Pure ADT group (Only received castration therapy (surgical castration or medical castration), without combining any other systemic treatments
):None
ADT+ARPI (ADT combined with new endocrine drugs (abiraterone, enzalutamide, darolutamide, etc.), with standardized medication use and no serious medication adherence issues during follow-up
ADT + chemotherapy group (ADT combined with chemotherapy drugs (such as docetaxel), and the chemotherapy regimen meets the requirements of clinical diagnosis and treatment guidelines
Sponsors
Zibo Central Hospital
Eligibility
Sex/Gender
Male
Age
18 Years to 85 Years
Inclusion criteria
Inclusion criteria: 1. Histologically confirmed as prostatic acinar adenocarcinoma (pathological sections confirmed by review by more than 2 pathologists); 2. Imaging examinations (CT/MRI, bone scan, PSMA-PET/CT) confirmed the presence of distant metastases (bone, lymph nodes, viscera, etc.), meeting the diagnostic criteria for metastatic prostate cancer; 3. Aged >= 18 years, with an Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2, able to tolerate systemic treatment, and without severe organ dysfunction; 4. Complete clinical data (including baseline data, treatment plans, follow-up records, etc.) and able to cooperate in completing the full course of follow-up (follow-up duration >= 6 months); 5. Patients and their families voluntarily signed the informed consent form, agreed to participate in this study, authorized the use of their clinical data for scientific research analysis, were aware of the research risks, and were willing to cooperate with follow-up.
Exclusion criteria
Exclusion criteria: 1. Pathological subtypes are non-acinar adenocarcinoma subtypes such as ductal adenocarcinoma and neuroendocrine differentiation; 2. Complicated with other malignant tumors, severe organ failure of heart, liver, kidney, lung, etc., unable to tolerate follow-up or study-related assessments; 3. Previous receipt of systemic treatment for prostate cancer (such as ADT, chemotherapy, targeted therapy, etc.), or presence of relevant treatment contraindications; 4. Severe lack of clinical data that cannot be supplemented, or expected high loss to follow-up rate (>20%), making it impossible to complete the study follow-up; 5. Refusal to sign the informed consent form, or presence of mental illness, cognitive impairment, etc., which makes it impossible to cooperate with the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Prostate Specific Antigen (PSA) response rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Objective Response Rate (ORR);Disease Control Rate (DCR); | — |
Countries
China
Contacts
Public ContactMeng Yang
Zibo Central Hospital, Shandong Province
Outcome results
None listed